ZNF143

Across TCGA pan-cancer cohorts, ZNF143 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF143 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZNF143 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF143 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, PRAD, and LGG are the cancer types where ZNF143 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
PRAD	DFS	Median	All	0.105	0.776	<.001	6	view →
LGG	OS	Median	All	0.300	0.830	.004	6	view →
COAD	DFS	Median	All	0.160	0.693	.020	6	view →
LUAD	DFS	Median	All	0.229	0.813	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.628	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNF143–SCLC (DFS)

Open the SCLC breakdown →